Quince Therapeutics (QNCX) releases Phase 3 NEAT eDSP trial results in ataxia-telangiectasia

Rhea-AI Filing Summary

Quince Therapeutics, Inc. filed a current report to note that it has released top-line clinical data from a major late-stage study. On January 29, 2026, the company issued a press release with results from its pivotal Phase 3 NEAT clinical trial of eDSP in ataxia-telangiectasia, a serious inherited disorder. The press release, attached as Exhibit 99.1, contains the detailed trial outcomes and is incorporated by reference into this report.

Insights

Biopharma clinical-stage analyst

Quince disclosed pivotal Phase 3 NEAT trial results for eDSP in ataxia-telangiectasia via an attached press release.

The company states that it has released results from its pivotal Phase 3 NEAT clinical trial of eDSP in ataxia-telangiectasia, with full details provided in an attached press release. A pivotal Phase 3 study is typically designed to support potential regulatory decisions, so this represents an important development in the eDSP program.

The excerpt does not describe whether the trial met its endpoints or characterize the results as favorable or unfavorable. Any impact on Quince’s outlook will depend on the specific efficacy and safety data, which are contained in Exhibit 99.1 referenced here.

false 0001662774 0001662774 2026-01-29 2026-01-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 29, 2026

Quince Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-38890		90-1024039
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

611 Gateway Boulevard Suite 273
South San Francisco, California		94080
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (415) 910-5717

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		QNCX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item. 8.01 Other Events.

On January 29, 2026, Quince Therapeutics, Inc. issued a press release announcing results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release issued by Quince Therapeutics, Inc. dated January 29, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				QUINCE THERAPEUTICS, INC.
Date: January 29, 2026				By:
				Name:		Dirk Thye
				Title:		Chief Executive Officer and Chief Medical Officer

FAQ

What did Quince Therapeutics (QNCX) report in its latest 8-K filing?

Quince Therapeutics reported that it issued a press release with results from its pivotal Phase 3 NEAT clinical trial of eDSP in ataxia-telangiectasia. The detailed clinical outcomes are provided in the press release attached as Exhibit 99.1 to the report.

Which clinical trial did Quince Therapeutics (QNCX) discuss in this 8-K?

The 8-K discusses the pivotal Phase 3 NEAT clinical trial of eDSP in ataxia-telangiectasia. Quince Therapeutics states it has issued a press release announcing the results of this trial, and that press release is included as Exhibit 99.1 and incorporated by reference.

How did Quince Therapeutics (QNCX) communicate its Phase 3 NEAT trial results?

Quince Therapeutics communicated its Phase 3 NEAT NEAT trial results through a press release dated January 29, 2026. The 8-K filing notes that this press release is attached as Exhibit 99.1 and is incorporated by reference for full clinical and trial details.

What is the role of eDSP in Quince Therapeutics’ latest 8-K disclosure?

In this disclosure, eDSP is the investigational therapy evaluated in the pivotal Phase 3 NEAT clinical trial for ataxia-telangiectasia. Quince Therapeutics states that it has issued a press release with the trial’s results, which is attached to the report as Exhibit 99.1.

Does the Quince Therapeutics (QNCX) 8-K describe whether the NEAT trial was successful?

The 8-K itself does not characterize the NEAT trial as successful or unsuccessful. It only states that Quince issued a press release announcing results from the pivotal Phase 3 NEAT trial of eDSP in ataxia-telangiectasia, with full results contained in Exhibit 99.1.